226 related articles for article (PubMed ID: 36516200)
1. Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).
Zhang C; Al-Shaheri FN; Alhamdani MSS; Bauer AS; Hoheisel JD; Schenk M; Hinz U; Goedecke P; Al-Halabi K; Büchler MW; Giese NA; Hackert T; Roth S
Clin Cancer Res; 2023 Apr; 29(8):1535-1545. PubMed ID: 36516200
[TBL] [Abstract][Full Text] [Related]
2. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
6. An integrated analysis of host- and tumor-derived markers for predicting high-grade dysplasia and associated invasive carcinoma of intraductal papillary mucinous neoplasms of the pancreas.
Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Naitoh T; Furukawa T; Unno M
Surg Today; 2020 Sep; 50(9):1039-1048. PubMed ID: 32124086
[TBL] [Abstract][Full Text] [Related]
7. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.
Tulla KA; Maker AV
Langenbecks Arch Surg; 2018 Mar; 403(2):151-194. PubMed ID: 29218397
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
[TBL] [Abstract][Full Text] [Related]
9. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology.
Omori Y; Furukawa T; Scarpa A; Luchini C
J Clin Pathol; 2023 Nov; 76(11):734-739. PubMed ID: 37500498
[TBL] [Abstract][Full Text] [Related]
10. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
11. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic
Fujikura K; Hosoda W; Felsenstein M; Song Q; Reiter JG; Zheng L; Beleva Guthrie V; Rincon N; Dal Molin M; Dudley J; Cohen JD; Wang P; Fischer CG; Braxton AM; Noë M; Jongepier M; Fernández-Del Castillo C; Mino-Kenudson M; Schmidt CM; Yip-Schneider MT; Lawlor RT; Salvia R; Roberts NJ; Thompson ED; Karchin R; Lennon AM; Jiao Y; Wood LD
Gut; 2021 May; 70(5):928-939. PubMed ID: 33028669
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E
Yip-Schneider MT; Carr RA; Wu H; Schmidt CM
J Am Coll Surg; 2017 Oct; 225(4):481-487. PubMed ID: 28739154
[TBL] [Abstract][Full Text] [Related]
13. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
14. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
[TBL] [Abstract][Full Text] [Related]
15. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
Das KK; Xiao H; Geng X; Fernandez-Del-Castillo C; Morales-Oyarvide V; Daglilar E; Forcione DG; Bounds BC; Brugge WR; Pitman MB; Mino-Kenudson M; Das KM
Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
[TBL] [Abstract][Full Text] [Related]
16. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
Michaels PJ; Brachtel EF; Bounds BC; Brugge WR; Pitman MB
Cancer; 2006 Jun; 108(3):163-73. PubMed ID: 16550572
[TBL] [Abstract][Full Text] [Related]
17. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
[TBL] [Abstract][Full Text] [Related]
18. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
